Integra LifeSciences Holdings Corporation (NASDAQ:IART) Given Average Rating of “Reduce” by Analysts

Posted by George Bondi on Jul 30th, 2026

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART – Get Free Report) have been given a consensus recommendation of “Reduce” by the eight research firms that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $18.8571.

A number of research firms have commented on IART. UBS Group started coverage on Integra LifeSciences in a report on Tuesday. They set a “neutral” rating and a $19.00 target price on the stock. Citigroup reissued a “neutral” rating and set a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. Weiss Ratings upgraded Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. Truist Financial lifted their price objective on shares of Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a report on Thursday, July 16th. Finally, Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a report on Thursday, June 18th.

Get Our Latest Research Report on IART

Institutional Investors Weigh In On Integra LifeSciences

Several institutional investors and hedge funds have recently bought and sold shares of IART. Glenmede Trust Co. NA boosted its stake in Integra LifeSciences by 27.4% in the first quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock valued at $9,276,000 after acquiring an additional 211,774 shares during the period. Access Investment Management LLC raised its position in shares of Integra LifeSciences by 72.0% during the 1st quarter. Access Investment Management LLC now owns 640,535 shares of the life sciences company’s stock worth $6,034,000 after purchasing an additional 268,085 shares during the period. Bank of America Corp DE lifted its holdings in shares of Integra LifeSciences by 71.4% in the 1st quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock worth $13,325,000 after purchasing an additional 589,408 shares during the last quarter. Amundi boosted its position in Integra LifeSciences by 80.8% during the 1st quarter. Amundi now owns 19,430 shares of the life sciences company’s stock valued at $183,000 after purchasing an additional 8,681 shares during the period. Finally, Maverick Capital Ltd. bought a new position in Integra LifeSciences during the 1st quarter worth $679,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

Trending Headlines about Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

Positive Sentiment: Q2 earnings exceeded expectations. Integra reported adjusted earnings of $0.56 per share, above the $0.48 consensus and up from $0.45 a year earlier. Revenue of $418.8 million was slightly ahead of the $417.5 million estimate. Integra LifeSciences Reports Second Quarter 2026 Financial Results
Positive Sentiment: Technical momentum remains a supporting factor. Zacks identified IART as one of three stocks showing breakout potential, noting that the shares were trading near their 52-week high after passing technical screens. 3 Stocks Showing Breakout Potential Ahead of August
Neutral Sentiment: UBS initiated research coverage. The new coverage may increase institutional attention, although the available report does not specify UBS’s rating or price target. UBS Group Begins Coverage on Integra LifeSciences
Negative Sentiment: Forward guidance was generally in line rather than a major upgrade. Integra forecast third-quarter EPS of $0.53–$0.61 and revenue of $410 million–$425 million, compared with consensus of $0.56 and $417.3 million. Full-year EPS guidance of $2.40–$2.50 also brackets the $2.45 consensus, while revenue guidance was approximately $1.7 billion. The lack of a meaningful guidance increase may be weighing on the stock despite the Q2 beat. Integra LifeSciences Q2 2026 Earnings Call Transcript

Integra LifeSciences Trading Up 7.8%

NASDAQ IART traded up $1.28 during mid-day trading on Thursday, hitting $17.77. The company’s stock had a trading volume of 138,886 shares, compared to its average volume of 902,607. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.38 and a quick ratio of 1.95. Integra LifeSciences has a 52-week low of $8.70 and a 52-week high of $20.49. The stock’s fifty day simple moving average is $17.63 and its two-hundred day simple moving average is $13.42. The firm has a market capitalization of $1.38 billion, a P/E ratio of -2.74, a price-to-earnings-growth ratio of 1.37 and a beta of 1.22.

Integra LifeSciences (NASDAQ:IART – Get Free Report) last announced its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.08. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The company had revenue of $418.76 million for the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Research analysts expect that Integra LifeSciences will post 2.45 EPS for the current year.

About Integra LifeSciences

(Get Free Report)

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.